APP and Alzheimer disease: Together, these data suggest that miR-181a protects against pericyte loss and vascular damage during AD development, offering an implication that the ameliorated cognitive deficits (Figure 2) and reduced amyloid plaque deposition (Figure 3) in APP/PS1 mice by miR-181a are associated with the protected pericytes and prevented BBB breakdown.